{ "data": { "id": "org_national-healthcare-security-administration", "slug": "national-healthcare-security-administration", "name": "National Healthcare Security Administration", "short_name": "NHSA", "type": "government", "tier": 1, "homepage": "https://www.nhsa.gov.cn", "country_code": "CN", "reliability_note": null, "url": "https://statorigin.org/sources/national-healthcare-security-administration", "documents": [ { "title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "doc_type": "press_release", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 14 }, { "title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 14 }, { "title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 14 }, { "title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 7 }, { "title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 18 }, { "title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 7 } ], "statistics": [ { "id": "stat_YBYHGK0ZP18XJ17TE3M39MKSD4", "url": "https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4", "indicator": { "slug": "beneficiaries-of-negotiated-reimbursement-drugs", "name": "Beneficiaries of negotiated reimbursement drugs", "definition": "Cumulative count of patient visits or individuals benefiting from price-negotiated reimbursement medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 830, "value_text": "8.3亿人次", "unit": "count", "currency": null, "scale": "million", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "截至2024年10月底，协议期内谈判药品累计受益8.3亿人次，累计为患者减负超8800亿元，充分彰显党和政府对人民健康福祉的高度关切。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4", "bibtex": "@misc{nhsa2024beneficiaries9mksd4,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1D7K70JPV4F1B4X53S0XCSEM96", "url": "https://statorigin.org/stat/stat_1D7K70JPV4F1B4X53S0XCSEM96", "indicator": { "slug": "centralized-procurement-drugs-added-to-national-reimbursement-drug-list", "name": "Centralized procurement drugs added to national reimbursement drug list", "definition": "Number of drugs winning bids in volume-based procurement directly included into a national reimbursement drug list." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-11-28", "type": "point" }, "value": 2, "value_text": "2种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "在今年的调整中，有91种药品新增进入国家医保药品目录，其中89种以谈判/竞价方式纳入，另有2种国家集采中选药品直接纳入，同时43种临床已被替代或长期未生产供应的药品被调出。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_1D7K70JPV4F1B4X53S0XCSEM96", "bibtex": "@misc{nhsa2024centralizedcsem96,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1D7K70JPV4F1B4X53S0XCSEM96},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_20KAVP0JDSCT0QSHHFHFN0978Z", "url": "https://statorigin.org/stat/stat_20KAVP0JDSCT0QSHHFHFN0978Z", "indicator": { "slug": "cumulative-drugs-added-via-negotiation-in-reimbursement-drug-list", "name": "Cumulative drugs added via negotiation in reimbursement drug list", "definition": "Cumulative number of drugs added to a reimbursement drug formulary through price negotiations." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-05-31", "end": "2024-11-28", "type": "point" }, "value": 530, "value_text": "530种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "自成立以来，国家医保局已连续7年开展药品目录调整工作，累计将835种药品新增进入国家医保药品目录，其中谈判新增530种，竞价新增38种。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_20KAVP0JDSCT0QSHHFHFN0978Z", "bibtex": "@misc{nhsa2024cumulativen0978z,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_20KAVP0JDSCT0QSHHFHFN0978Z},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6", "url": "https://statorigin.org/stat/stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6", "indicator": { "slug": "cumulative-drugs-removed-from-reimbursement-drug-list", "name": "Cumulative drugs removed from reimbursement drug list", "definition": "Cumulative number of drugs delisted or phased out from a reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-05-31", "end": "2024-11-28", "type": "point" }, "value": 438, "value_text": "438种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "同时438种疗效不确切或易滥用、临床已被淘汰、长期未生产供应且可被其他品种替代的药品被调出目录。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6", "bibtex": "@misc{nhsa2024cumulativepxj5e6,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_FQKK442S68TP34CE2YQA8Y69Y6", "url": "https://statorigin.org/stat/stat_FQKK442S68TP34CE2YQA8Y69Y6", "indicator": { "slug": "cumulative-newly-added-drugs-in-reimbursement-drug-list", "name": "Cumulative newly added drugs in reimbursement drug list", "definition": "Cumulative number of drugs newly added to a reimbursement drug formulary across adjustment cycles." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-05-31", "end": "2024-11-28", "type": "point" }, "value": 835, "value_text": "835种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "自成立以来，国家医保局已连续7年开展药品目录调整工作，累计将835种药品新增进入国家医保药品目录，其中谈判新增530种，竞价新增38种。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_FQKK442S68TP34CE2YQA8Y69Y6", "bibtex": "@misc{nhsa2024cumulative8y69y6,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_FQKK442S68TP34CE2YQA8Y69Y6},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VEV3PWG150363YY6MZ64Q5ZNDV", "url": "https://statorigin.org/stat/stat_VEV3PWG150363YY6MZ64Q5ZNDV", "indicator": { "slug": "cumulative-patient-burden-reduction-from-negotiated-drugs", "name": "Cumulative patient burden reduction from negotiated drugs", "definition": "Cumulative out-of-pocket healthcare expense savings achieved by patients through price-negotiated reimbursement drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 880, "value_text": "超8800亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "截至2024年10月底，协议期内谈判药品累计受益8.3亿人次，累计为患者减负超8800亿元，充分彰显党和政府对人民健康福祉的高度关切。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_VEV3PWG150363YY6MZ64Q5ZNDV", "bibtex": "@misc{nhsa2024cumulativeq5zndv,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VEV3PWG150363YY6MZ64Q5ZNDV},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_M23GSF97A0BYCQ4S805T8FZ461", "url": "https://statorigin.org/stat/stat_M23GSF97A0BYCQ4S805T8FZ461", "indicator": { "slug": "drugs-removed-from-national-reimbursement-drug-list-year-to-date", "name": "Drugs removed from national reimbursement drug list (year to date)", "definition": "Count of drugs excluded or delisted from a national reimbursement drug list during a catalog adjustment cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-11-28", "type": "point" }, "value": 43, "value_text": "43种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "在今年的调整中，有91种药品新增进入国家医保药品目录，其中89种以谈判/竞价方式纳入，另有2种国家集采中选药品直接纳入，同时43种临床已被替代或长期未生产供应的药品被调出。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_M23GSF97A0BYCQ4S805T8FZ461", "bibtex": "@misc{nhsa2024drugs8fz461,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_M23GSF97A0BYCQ4S805T8FZ461},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_N8Q2NC2QP5ZGZNGZN0TYAVND87", "url": "https://statorigin.org/stat/stat_N8Q2NC2QP5ZGZNGZN0TYAVND87", "indicator": { "slug": "negotiated-or-bid-drugs-added-to-national-reimbursement-drug-list", "name": "Negotiated or bid drugs added to national reimbursement drug list", "definition": "Number of drugs admitted to a national reimbursement drug list through price negotiations or competitive bidding." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-11-28", "type": "point" }, "value": 89, "value_text": "89种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "在今年的调整中，有91种药品新增进入国家医保药品目录，其中89种以谈判/竞价方式纳入，另有2种国家集采中选药品直接纳入，同时43种临床已被替代或长期未生产供应的药品被调出。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_N8Q2NC2QP5ZGZNGZN0TYAVND87", "bibtex": "@misc{nhsa2024negotiatedavnd87,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_N8Q2NC2QP5ZGZNGZN0TYAVND87},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_32N52F4F2E7TCQQKREGX2D2M1P", "url": "https://statorigin.org/stat/stat_32N52F4F2E7TCQQKREGX2D2M1P", "indicator": { "slug": "newly-added-drugs-in-national-reimbursement-drug-list", "name": "Newly added drugs in national reimbursement drug list", "definition": "Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-11-28", "type": "point" }, "value": 91, "value_text": "91种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "在今年的调整中，有91种药品新增进入国家医保药品目录，其中89种以谈判/竞价方式纳入，另有2种国家集采中选药品直接纳入，同时43种临床已被替代或长期未生产供应的药品被调出。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_32N52F4F2E7TCQQKREGX2D2M1P", "bibtex": "@misc{nhsa2024newly2d2m1p,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_32N52F4F2E7TCQQKREGX2D2M1P},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_13CAH4PQ6B9H0DVDRM11CFZT86", "url": "https://statorigin.org/stat/stat_13CAH4PQ6B9H0DVDRM11CFZT86", "indicator": { "slug": "off-catalog-drugs-participating-in-price-negotiation-or-bidding", "name": "Off-catalog drugs participating in price negotiation or bidding", "definition": "Number of drugs currently outside a national reimbursement list participating in price negotiations or competitive bidding." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-11-28", "type": "point" }, "value": 117, "value_text": "117种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "今年参与谈判/竞价的117种目录外药品中，89种谈判或竞价成功，成功率和价格降幅与往年基本相当。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_13CAH4PQ6B9H0DVDRM11CFZT86", "bibtex": "@misc{nhsa2024catalogcfzt86,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_13CAH4PQ6B9H0DVDRM11CFZT86},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_P3PK9D56429BN9AX73946Y66N1", "url": "https://statorigin.org/stat/stat_P3PK9D56429BN9AX73946Y66N1", "indicator": { "slug": "reimbursement-drug-list-conventional-medicines", "name": "Reimbursement drug list conventional medicines", "definition": "Total number of conventional chemical medicines included in a reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-11-28", "end": "2024-11-28", "type": "point" }, "value": 1765, "value_text": "1765种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "本轮调整后，国家医保药品目录内药品总数达到3159种，其中西药1765种、中成药1394种。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_P3PK9D56429BN9AX73946Y66N1", "bibtex": "@misc{nhsa2024reimbursement6y66n1,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_P3PK9D56429BN9AX73946Y66N1},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_6S09ZWQKJ6CWJ58G73DRGXWD86", "url": "https://statorigin.org/stat/stat_6S09ZWQKJ6CWJ58G73DRGXWD86", "indicator": { "slug": "reimbursement-drug-list-total-drugs", "name": "Reimbursement drug list total drugs", "definition": "Total number of pharmaceutical products covered by a national or public reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-11-28", "end": "2024-11-28", "type": "point" }, "value": 3159, "value_text": "3159种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "本轮调整后，国家医保药品目录内药品总数达到3159种，其中西药1765种、中成药1394种。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_6S09ZWQKJ6CWJ58G73DRGXWD86", "bibtex": "@misc{nhsa2024reimbursementgxwd86,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_6S09ZWQKJ6CWJ58G73DRGXWD86},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_EM7HNX19M5HK0C846TXA7YE7EF", "url": "https://statorigin.org/stat/stat_EM7HNX19M5HK0C846TXA7YE7EF", "indicator": { "slug": "reimbursement-drug-list-traditional-patent-medicines", "name": "Reimbursement drug list traditional patent medicines", "definition": "Total number of proprietary traditional medicines included in a reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-11-28", "end": "2024-11-28", "type": "point" }, "value": 1394, "value_text": "1394种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "本轮调整后，国家医保药品目录内药品总数达到3159种，其中西药1765种、中成药1394种。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_EM7HNX19M5HK0C846TXA7YE7EF", "bibtex": "@misc{nhsa2024reimbursement7ye7ef,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EM7HNX19M5HK0C846TXA7YE7EF},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_PFHYPSVQ2FAKK80MW8Z37RDH1K", "url": "https://statorigin.org/stat/stat_PFHYPSVQ2FAKK80MW8Z37RDH1K", "indicator": { "slug": "successful-price-negotiations-or-bids-for-off-catalog-drugs", "name": "Successful price negotiations or bids for off-catalog drugs", "definition": "Count of off-catalog drugs that reached successful price agreements via negotiations or competitive bidding." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-11-28", "type": "point" }, "value": 89, "value_text": "89种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "今年参与谈判/竞价的117种目录外药品中，89种谈判或竞价成功，成功率和价格降幅与往年基本相当。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_PFHYPSVQ2FAKK80MW8Z37RDH1K", "bibtex": "@misc{nhsa2024successful7rdh1k,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PFHYPSVQ2FAKK80MW8Z37RDH1K},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_5XWSVWS6KHPM8RN9H08ECKWYJX", "url": "https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX", "indicator": { "slug": "approved-class-1-innovative-drugs", "name": "Approved Class 1 innovative drugs", "definition": "Total number of Class 1 innovative drugs approved for marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 76, "value_text": "76个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "大众新闻大众日报记者提问", "quote": "2025年批准上市的76个1类创新药中，既有我国本土企业原创的“全球新”，也有部分跨国企业在我国实现的“全球首发”。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX", "bibtex": "@misc{nhsa2025approvedckwyjx,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9", "url": "https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9", "indicator": { "slug": "approved-class-1-innovative-drugs-half-year", "name": "Approved Class 1 innovative drugs (half year)", "definition": "Total number of Class 1 innovative drugs approved for marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 38, "value_text": "38个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "记者今天从国家药监局获悉，最新统计显示，今年上半年我国批准38个1类创新药上市。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9", "bibtex": "@misc{nhsa2026approved10svf9,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1WGYBP9BMEKJBY30RP8KX65K3G", "url": "https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G", "indicator": { "slug": "approved-drug-marketing-registration-applications-half-year", "name": "Approved drug marketing registration applications (half year)", "definition": "Total number of drug marketing registration applications approved by the regulatory authority." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 2318, "value_text": "2318件", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "国家药监局药品注册管理司副司长蓝恭涛表示，截至6月底，国家药监局今年共批准药品上市注册申请2318件，其中“全球新”创新药38个，包括20个化学药品，17个生物制品和1个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G", "bibtex": "@misc{nhsa2026approvedx65k3g,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VXVARPPSBWC8A6ZCKDBPQNRYD3", "url": "https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3", "indicator": { "slug": "approved-innovative-drugs-with-new-targets-or-mechanisms", "name": "Approved innovative drugs with new targets or mechanisms", "definition": "Total number of innovative drugs with novel biological targets or mechanisms of action approved for marketing." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 11, "value_text": "11个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "据介绍，今年上半年批准上市的38个创新药中，有11个是新靶点、新机制的药品，并且均为自主研发的国产创新药；而2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3", "bibtex": "@misc{nhsa2025approvedqnryd3,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_RYGSZH3DKE8N9CQ1G9B03GV1VA", "url": "https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA", "indicator": { "slug": "approved-innovative-drugs-with-new-targets-or-mechanisms-half-year", "name": "Approved innovative drugs with new targets or mechanisms (half year)", "definition": "Total number of innovative drugs with novel biological targets or mechanisms of action approved for marketing." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 11, "value_text": "11个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "据介绍，今年上半年批准上市的38个创新药中，有11个是新靶点、新机制的药品，并且均为自主研发的国产创新药；而2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA", "bibtex": "@misc{nhsa2026approved3gv1va,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_FXX75R17XTD8EC3NEN7WD7C6RW", "url": "https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW", "indicator": { "slug": "bioequivalence-trials", "name": "Bioequivalence trials", "definition": "Total number of registered bioequivalence trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2218, "value_text": "2218项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW", "bibtex": "@misc{nhsa2025bioequivalenced7c6rw,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HEBDQ5W4X21WJNF05KTYPFNKZQ", "url": "https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ", "indicator": { "slug": "bioequivalence-trials-share", "name": "Bioequivalence trials share", "definition": "Share of bioequivalence trials in total registered clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 42.5, "value_text": "42.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ", "bibtex": "@misc{nhsa2025bioequivalencepfnkzq,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9", "url": "https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9", "indicator": { "slug": "category-1-innovative-drugs-added-to-national-health-insurance-catalog", "name": "Category 1 innovative drugs added to national health insurance catalog", "definition": "Number of category 1 innovative drugs newly added to the national health insurance drug catalog." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 50, "value_text": "50", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "经相应程序，本次目录调整新增114种药品，其中50种1类创新药，同时调出了29种临床没有供应或可被其他药物更好替代的药品（其中9种尚有相同治疗主成分的其他剂型在目录内，不减少目录编号）。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9", "bibtex": "@misc{nhsa2025categorywkgds9,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5", "url": "https://statorigin.org/stat/stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5", "indicator": { "slug": "class-1-innovative-drug-clinical-trials", "name": "Class 1 innovative drug clinical trials", "definition": "Number of clinical trials registered for Class 1 innovative drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2171, "value_text": "2171项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "新药临床试验近六成 其中超七成是创新药", "quote": "报告显示，2025年我国登记的2997项新药临床试验中，1类创新药有2171项，占比72.4%，同比增长4.1%；1类创新药临床试验抗肿瘤药物占比较高，占总体的37.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5", "bibtex": "@misc{nhsa2025classkpdrg5,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_XBDEETFHREBH7K3QRCNXDVAHPE", "url": "https://statorigin.org/stat/stat_XBDEETFHREBH7K3QRCNXDVAHPE", "indicator": { "slug": "class-1-innovative-drug-clinical-trials-growth-rate", "name": "Class 1 innovative drug clinical trials growth rate", "definition": "Year-over-year percentage growth in Class 1 innovative drug clinical trial registrations." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4.1, "value_text": "4.1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "新药临床试验近六成 其中超七成是创新药", "quote": "报告显示，2025年我国登记的2997项新药临床试验中，1类创新药有2171项，占比72.4%，同比增长4.1%；1类创新药临床试验抗肿瘤药物占比较高，占总体的37.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_XBDEETFHREBH7K3QRCNXDVAHPE", "bibtex": "@misc{nhsa2025classdvahpe,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XBDEETFHREBH7K3QRCNXDVAHPE},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP", "url": "https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP", "indicator": { "slug": "class-1-innovative-drug-clinical-trials-share", "name": "Class 1 innovative drug clinical trials share", "definition": "Share of Class 1 innovative drug clinical trials among all new drug clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 72.4, "value_text": "72.4%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "新药临床试验近六成 其中超七成是创新药", "quote": "报告显示，2025年我国登记的2997项新药临床试验中，1类创新药有2171项，占比72.4%，同比增长4.1%；1类创新药临床试验抗肿瘤药物占比较高，占总体的37.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP", "bibtex": "@misc{nhsa2025classvtw4mp,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_KRH03AR8MZ5JYVWYGK6AC7JSPC", "url": "https://statorigin.org/stat/stat_KRH03AR8MZ5JYVWYGK6AC7JSPC", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 5215, "value_text": "5215项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "quote": "国家药监局药审中心副主任杨志敏介绍，2025年，国家药监局收到临床试验登记总量5215项，同比增长6.4%，创历史新高，较2020年翻一番。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_KRH03AR8MZ5JYVWYGK6AC7JSPC", "bibtex": "@misc{nhsa2025clinicalc7jspc,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KRH03AR8MZ5JYVWYGK6AC7JSPC},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM", "url": "https://statorigin.org/stat/stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM", "indicator": { "slug": "clinical-trial-registrations-growth-rate", "name": "Clinical trial registrations growth rate", "definition": "Year-over-year percentage growth in total drug clinical trial registrations." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 6.4, "value_text": "6.4%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "quote": "国家药监局药审中心副主任杨志敏介绍，2025年，国家药监局收到临床试验登记总量5215项，同比增长6.4%，创历史新高，较2020年翻一番。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM", "bibtex": "@misc{nhsa2025clinicalvs1pym,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_YNSMX436YHHD8Z81G9V98C62GK", "url": "https://statorigin.org/stat/stat_YNSMX436YHHD8Z81G9V98C62GK", "indicator": { "slug": "domestic-first-in-class-drug-approvals", "name": "Domestic first-in-class drug approvals", "definition": "Number of approved first-in-class drugs with novel mechanisms of action originated by domestic developers." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4, "value_text": "4个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "2025年我国批准的首创新药为11个，其中4个是我国自主研发的。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_YNSMX436YHHD8Z81G9V98C62GK", "bibtex": "@misc{nhsa2025domestic8c62gk,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YNSMX436YHHD8Z81G9V98C62GK},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_PJ5VPBW3DD20GZHP95QV5524P7", "url": "https://statorigin.org/stat/stat_PJ5VPBW3DD20GZHP95QV5524P7", "indicator": { "slug": "domestic-innovative-biological-product-approvals", "name": "Domestic innovative biological product approvals", "definition": "Number of domestically originated innovative biological medicines granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 21, "value_text": "21个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_PJ5VPBW3DD20GZHP95QV5524P7", "bibtex": "@misc{nhsa2025domestic5524p7,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PJ5VPBW3DD20GZHP95QV5524P7},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_P51Z5CB5E0RWSQBPPWKJGKRP5W", "url": "https://statorigin.org/stat/stat_P51Z5CB5E0RWSQBPPWKJGKRP5W", "indicator": { "slug": "domestic-innovative-chemical-drug-approvals", "name": "Domestic innovative chemical drug approvals", "definition": "Number of domestically originated innovative chemical drugs granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 38, "value_text": "38个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_P51Z5CB5E0RWSQBPPWKJGKRP5W", "bibtex": "@misc{nhsa2025domesticgkrp5w,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_P51Z5CB5E0RWSQBPPWKJGKRP5W},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_3CS30NJVR5F2ZBEJCT0NVR07TH", "url": "https://statorigin.org/stat/stat_3CS30NJVR5F2ZBEJCT0NVR07TH", "indicator": { "slug": "domestic-share-of-approved-innovative-biological-products", "name": "Domestic share of approved innovative biological products", "definition": "Proportion of approved innovative biological medicines accounted for by domestic developers." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 91.3, "value_text": "91.30%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_3CS30NJVR5F2ZBEJCT0NVR07TH", "bibtex": "@misc{nhsa2025domesticvr07th,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_3CS30NJVR5F2ZBEJCT0NVR07TH},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Z57X7RFVEX6037DQ9XB77JEN6M", "url": "https://statorigin.org/stat/stat_Z57X7RFVEX6037DQ9XB77JEN6M", "indicator": { "slug": "domestic-share-of-approved-innovative-chemical-drugs", "name": "Domestic share of approved innovative chemical drugs", "definition": "Proportion of approved innovative chemical medicines accounted for by domestic developers." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 80.85, "value_text": "80.85%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_Z57X7RFVEX6037DQ9XB77JEN6M", "bibtex": "@misc{nhsa2025domestic7jen6m,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Z57X7RFVEX6037DQ9XB77JEN6M},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_QDCHKD8FKHRZ06GBEXXJ8D7D7T", "url": "https://statorigin.org/stat/stat_QDCHKD8FKHRZ06GBEXXJ8D7D7T", "indicator": { "slug": "drug-clinical-trials", "name": "Drug clinical trials", "definition": "Total number of drug clinical trials initiated or conducted in a given period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 5000, "value_text": "5000项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "我国上半年创新药对外授权约1100亿美元 创历史新高", "quote": "据了解，我国每年新增药物临床试验数量呈持续增长态势，2025年临床试验总量首次突破5000项，创历史新高，其中，新药临床试验2997项，占比57.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_QDCHKD8FKHRZ06GBEXXJ8D7D7T", "bibtex": "@misc{nhsa2025drug8d7d7t,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QDCHKD8FKHRZ06GBEXXJ8D7D7T},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HB3M5YEVAWDH3AB6EWAC6X1STC", "url": "https://statorigin.org/stat/stat_HB3M5YEVAWDH3AB6EWAC6X1STC", "indicator": { "slug": "drugs-in-commercial-health-insurance-innovative-drug-catalog-annual", "name": "Drugs in commercial health insurance innovative drug catalog (annual)", "definition": "Total number of innovative drugs included in the commercial health insurance innovative drug catalog." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 19, "value_text": "19", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕见病治疗药品，还有社会关注度较高的阿尔茨海默病治疗药品，与基本医保形成较好的互补衔接，也为进一步厘清基本医保保障边界，推动商业健康保险与基本医保错位发展，建立多层次医疗保障体系奠定基础。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_HB3M5YEVAWDH3AB6EWAC6X1STC", "bibtex": "@misc{nhsa2025drugs6x1stc,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HB3M5YEVAWDH3AB6EWAC6X1STC},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_CJN8MP9741KDMVCDWV9FFVFXAY", "url": "https://statorigin.org/stat/stat_CJN8MP9741KDMVCDWV9FFVFXAY", "indicator": { "slug": "drugs-removed-from-national-reimbursement-drug-list", "name": "Drugs removed from national reimbursement drug list", "definition": "Count of drugs excluded or delisted from a national reimbursement drug list during a catalog adjustment cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 29, "value_text": "29", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "经相应程序，本次目录调整新增114种药品，其中50种1类创新药，同时调出了29种临床没有供应或可被其他药物更好替代的药品（其中9种尚有相同治疗主成分的其他剂型在目录内，不减少目录编号）。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_CJN8MP9741KDMVCDWV9FFVFXAY", "bibtex": "@misc{nhsa2025drugsfvfxay,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_CJN8MP9741KDMVCDWV9FFVFXAY},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_50VMAAXPT5DCRGKNXFMP7VT20B", "url": "https://statorigin.org/stat/stat_50VMAAXPT5DCRGKNXFMP7VT20B", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 11, "value_text": "11个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "2025年我国批准的首创新药为11个，其中4个是我国自主研发的。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_50VMAAXPT5DCRGKNXFMP7VT20B", "bibtex": "@misc{nhsa2025first7vt20b,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_50VMAAXPT5DCRGKNXFMP7VT20B},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HZK27CSQ2S4M3YHJWWVE559N8J", "url": "https://statorigin.org/stat/stat_HZK27CSQ2S4M3YHJWWVE559N8J", "indicator": { "slug": "imported-innovative-biological-product-approvals", "name": "Imported innovative biological product approvals", "definition": "Number of imported innovative biological medicines granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2, "value_text": "2个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_HZK27CSQ2S4M3YHJWWVE559N8J", "bibtex": "@misc{nhsa2025imported559n8j,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HZK27CSQ2S4M3YHJWWVE559N8J},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_EGW632GEEYYS535288TQVES0AE", "url": "https://statorigin.org/stat/stat_EGW632GEEYYS535288TQVES0AE", "indicator": { "slug": "imported-innovative-chemical-drug-approvals", "name": "Imported innovative chemical drug approvals", "definition": "Number of imported innovative chemical drugs granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 9, "value_text": "9个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_EGW632GEEYYS535288TQVES0AE", "bibtex": "@misc{nhsa2025importedves0ae,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EGW632GEEYYS535288TQVES0AE},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_4AA32VKE71HARRS7CSK2HMX4GH", "url": "https://statorigin.org/stat/stat_4AA32VKE71HARRS7CSK2HMX4GH", "indicator": { "slug": "innovative-biological-product-approvals", "name": "Innovative biological product approvals", "definition": "Total number of innovative biological medicines granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 23, "value_text": "23个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "据了解，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_4AA32VKE71HARRS7CSK2HMX4GH", "bibtex": "@misc{nhsa2025innovativehmx4gh,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_4AA32VKE71HARRS7CSK2HMX4GH},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_68SAW6G0Z4YJH1MEHPZT9TADHJ", "url": "https://statorigin.org/stat/stat_68SAW6G0Z4YJH1MEHPZT9TADHJ", "indicator": { "slug": "innovative-biological-product-approvals-half-year", "name": "Innovative biological product approvals (half year)", "definition": "Total number of innovative biological medicines granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 17, "value_text": "17个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "国家药监局药品注册管理司副司长蓝恭涛表示，截至6月底，国家药监局今年共批准药品上市注册申请2318件，其中“全球新”创新药38个，包括20个化学药品，17个生物制品和1个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_68SAW6G0Z4YJH1MEHPZT9TADHJ", "bibtex": "@misc{nhsa2026innovative9tadhj,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_68SAW6G0Z4YJH1MEHPZT9TADHJ},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_5CC4KTNWJX8KPYFG18VMMM88P6", "url": "https://statorigin.org/stat/stat_5CC4KTNWJX8KPYFG18VMMM88P6", "indicator": { "slug": "innovative-chemical-drug-approvals", "name": "Innovative chemical drug approvals", "definition": "Total number of innovative small molecule chemical drugs granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 47, "value_text": "47个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "据了解，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_5CC4KTNWJX8KPYFG18VMMM88P6", "bibtex": "@misc{nhsa2025innovativemm88p6,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_5CC4KTNWJX8KPYFG18VMMM88P6},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_0R53WSWM4JHBHBBN92T8D76D6K", "url": "https://statorigin.org/stat/stat_0R53WSWM4JHBHBBN92T8D76D6K", "indicator": { "slug": "innovative-chemical-drug-approvals-half-year", "name": "Innovative chemical drug approvals (half year)", "definition": "Total number of innovative small molecule chemical drugs granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 20, "value_text": "20个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "国家药监局药品注册管理司副司长蓝恭涛表示，截至6月底，国家药监局今年共批准药品上市注册申请2318件，其中“全球新”创新药38个，包括20个化学药品，17个生物制品和1个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_0R53WSWM4JHBHBBN92T8D76D6K", "bibtex": "@misc{nhsa2026innovatived76d6k,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_0R53WSWM4JHBHBBN92T8D76D6K},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_S8CD3FFWAD4ED7XVT24T434QX2", "url": "https://statorigin.org/stat/stat_S8CD3FFWAD4ED7XVT24T434QX2", "indicator": { "slug": "innovative-drug-approvals", "name": "Innovative drug approvals", "definition": "Total number of innovative pharmaceutical products granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 76, "value_text": "76个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "记者今天从国家药监局获悉，2025年我国已批准上市的创新药达76个，大幅超过2024年全年48个，创历史新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_S8CD3FFWAD4ED7XVT24T434QX2", "bibtex": "@misc{nhsa2025innovative434qx2,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_S8CD3FFWAD4ED7XVT24T434QX2},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_TGG4B688ZSKWTA83EKYANSYTNN", "url": "https://statorigin.org/stat/stat_TGG4B688ZSKWTA83EKYANSYTNN", "indicator": { "slug": "innovative-drug-approvals", "name": "Innovative drug approvals", "definition": "Total number of innovative pharmaceutical products granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 48, "value_text": "48个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "记者今天从国家药监局获悉，2025年我国已批准上市的创新药达76个，大幅超过2024年全年48个，创历史新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_TGG4B688ZSKWTA83EKYANSYTNN", "bibtex": "@misc{nhsa2024innovativensytnn,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_TGG4B688ZSKWTA83EKYANSYTNN},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_G3PFZ508S5HQAB04D81G94RCKW", "url": "https://statorigin.org/stat/stat_G3PFZ508S5HQAB04D81G94RCKW", "indicator": { "slug": "innovative-drug-approvals-year-to-date", "name": "Innovative drug approvals (year to date)", "definition": "Total number of innovative pharmaceutical products granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-04-15", "type": "point" }, "value": 14, "value_text": "14个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "大众新闻大众日报记者提问", "quote": "今年又有14个创新药获批上市，我国医药创新继续保持着良好势头。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_G3PFZ508S5HQAB04D81G94RCKW", "bibtex": "@misc{nhsa2026innovative94rckw,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_G3PFZ508S5HQAB04D81G94RCKW},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_BPYMDQ56441MRFHXWB295C2Y0R", "url": "https://statorigin.org/stat/stat_BPYMDQ56441MRFHXWB295C2Y0R", "indicator": { "slug": "innovative-drug-out-licensing-deal-count", "name": "Innovative drug out-licensing deal count", "definition": "Total number of out-licensing transactions concluded for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 150, "value_text": "超过150笔", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "此外，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，同样创历史新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_BPYMDQ56441MRFHXWB295C2Y0R", "bibtex": "@misc{nhsa2025innovative5c2y0r,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_BPYMDQ56441MRFHXWB295C2Y0R},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VBXTTVWGFRCZ02J6T0R07F9N7T", "url": "https://statorigin.org/stat/stat_VBXTTVWGFRCZ02J6T0R07F9N7T", "indicator": { "slug": "innovative-drug-out-licensing-deal-count", "name": "Innovative drug out-licensing deal count", "definition": "Total number of out-licensing transactions concluded for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 94, "value_text": "94笔", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "记者从国家药监局还获悉，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，远超2024年全年519亿美元和94笔，同样创历史新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_VBXTTVWGFRCZ02J6T0R07F9N7T", "bibtex": "@misc{nhsa2024innovative7f9n7t,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VBXTTVWGFRCZ02J6T0R07F9N7T},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_FRMSWXBPCDZJBYY4EP4PMTB2FB", "url": "https://statorigin.org/stat/stat_FRMSWXBPCDZJBYY4EP4PMTB2FB", "indicator": { "slug": "innovative-drug-out-licensing-deal-count-half-year", "name": "Innovative drug out-licensing deal count (half year)", "definition": "Total number of out-licensing transactions concluded for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 81, "value_text": "81笔", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "我国上半年创新药对外授权约1100亿美元 创历史新高", "quote": "最新统计显示，截至6月30日，我国创新药对外授权共81笔，交易总额约1100亿美元，达2025全年对外授权交易总额的80%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_FRMSWXBPCDZJBYY4EP4PMTB2FB", "bibtex": "@misc{nhsa2026innovativemtb2fb,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_FRMSWXBPCDZJBYY4EP4PMTB2FB},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_79NA9R5Y20KS9THXT2GAEH7BGW", "url": "https://statorigin.org/stat/stat_79NA9R5Y20KS9THXT2GAEH7BGW", "indicator": { "slug": "innovative-drug-out-licensing-deal-value", "name": "Innovative drug out-licensing deal value", "definition": "Total monetary value of out-licensing agreements signed for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 51.9, "value_text": "519亿美元", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "记者从国家药监局还获悉，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，远超2024年全年519亿美元和94笔，同样创历史新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_79NA9R5Y20KS9THXT2GAEH7BGW", "bibtex": "@misc{nhsa2024innovativeeh7bgw,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_79NA9R5Y20KS9THXT2GAEH7BGW},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_02X018QAC3T5KDRY83QYMRVDMR", "url": "https://statorigin.org/stat/stat_02X018QAC3T5KDRY83QYMRVDMR", "indicator": { "slug": "innovative-drug-out-licensing-deal-value", "name": "Innovative drug out-licensing deal value", "definition": "Total monetary value of out-licensing agreements signed for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 130, "value_text": "超1300亿美元", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "红星新闻记者提问", "quote": "2025年我国创新药海外授权交易总额超1300亿美元，这也是一个历史新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_02X018QAC3T5KDRY83QYMRVDMR", "bibtex": "@misc{nhsa2025innovativemrvdmr,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_02X018QAC3T5KDRY83QYMRVDMR},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_QP30HNGY7M4V13TE27HV4P4279", "url": "https://statorigin.org/stat/stat_QP30HNGY7M4V13TE27HV4P4279", "indicator": { "slug": "innovative-drug-out-licensing-deal-value", "name": "Innovative drug out-licensing deal value", "definition": "Total monetary value of out-licensing agreements signed for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 130, "value_text": "超过1300亿美元", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "此外，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，同样创历史新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T16:36:08.269Z", "confidence": 0.9, "is_secondhand": false, "supersedes": "stat_6Z4N8TVBN6FRWGC7JKPWX3W7HZ", "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_QP30HNGY7M4V13TE27HV4P4279", "bibtex": "@misc{nhsa2025innovative4p4279,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QP30HNGY7M4V13TE27HV4P4279},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T16:54:55.327Z" }, { "id": "stat_F85GSED465D9XYBVEA15Y0SHN0", "url": "https://statorigin.org/stat/stat_F85GSED465D9XYBVEA15Y0SHN0", "indicator": { "slug": "innovative-drug-out-licensing-deal-value-half-year", "name": "Innovative drug out-licensing deal value (half year)", "definition": "Total monetary value of out-licensing agreements signed for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 110, "value_text": "1100亿美元", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "我国上半年创新药对外授权约1100亿美元 创历史新高", "quote": "最新统计显示，截至6月30日，我国创新药对外授权共81笔，交易总额约1100亿美元，达2025全年对外授权交易总额的80%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_F85GSED465D9XYBVEA15Y0SHN0", "bibtex": "@misc{nhsa2026innovativey0shn0,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_F85GSED465D9XYBVEA15Y0SHN0},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Z0PVPC90D9EYSAZEYE6PQPGKEA", "url": "https://statorigin.org/stat/stat_Z0PVPC90D9EYSAZEYE6PQPGKEA", "indicator": { "slug": "innovative-traditional-medicine-approvals", "name": "Innovative traditional medicine approvals", "definition": "Total number of innovative traditional medicines granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 6, "value_text": "6个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "据了解，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_Z0PVPC90D9EYSAZEYE6PQPGKEA", "bibtex": "@misc{nhsa2025innovativeqpgkea,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Z0PVPC90D9EYSAZEYE6PQPGKEA},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VFE3M3TNP2TWT2A6YMYZNYAZKR", "url": "https://statorigin.org/stat/stat_VFE3M3TNP2TWT2A6YMYZNYAZKR", "indicator": { "slug": "innovative-traditional-medicine-approvals-half-year", "name": "Innovative traditional medicine approvals (half year)", "definition": "Total number of innovative traditional medicines granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 1, "value_text": "1个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "国家药监局药品注册管理司副司长蓝恭涛表示，截至6月底，国家药监局今年共批准药品上市注册申请2318件，其中“全球新”创新药38个，包括20个化学药品，17个生物制品和1个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_VFE3M3TNP2TWT2A6YMYZNYAZKR", "bibtex": "@misc{nhsa2026innovativenyazkr,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VFE3M3TNP2TWT2A6YMYZNYAZKR},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_512RH1Q64H70TFYGKGMVGDWKQ8", "url": "https://statorigin.org/stat/stat_512RH1Q64H70TFYGKGMVGDWKQ8", "indicator": { "slug": "international-multi-center-clinical-trials", "name": "International multi-center clinical trials", "definition": "Total number of registered international multi-center clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 410, "value_text": "410项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "我国2025年国际多中心临床试验410项", "quote": "报告显示，我国2025年国际多中心临床试验410项，占全年总量的13.7%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_512RH1Q64H70TFYGKGMVGDWKQ8", "bibtex": "@misc{nhsa2025internationalgdwkq8,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_512RH1Q64H70TFYGKGMVGDWKQ8},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_PM13405633HAGJF5PVDZWQ70VW", "url": "https://statorigin.org/stat/stat_PM13405633HAGJF5PVDZWQ70VW", "indicator": { "slug": "international-multi-center-clinical-trials-share", "name": "International multi-center clinical trials share", "definition": "Share of international multi-center clinical trials out of total registered clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 13.7, "value_text": "13.7%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "我国2025年国际多中心临床试验410项", "quote": "报告显示，我国2025年国际多中心临床试验410项，占全年总量的13.7%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_PM13405633HAGJF5PVDZWQ70VW", "bibtex": "@misc{nhsa2025internationalwq70vw,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PM13405633HAGJF5PVDZWQ70VW},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_JDPJRKETGMMTFGGV5QZQKZF26T", "url": "https://statorigin.org/stat/stat_JDPJRKETGMMTFGGV5QZQKZF26T", "indicator": { "slug": "negotiated-pharmaceutical-sales-driven-by-medical-insurance", "name": "Negotiated pharmaceutical sales driven by medical insurance", "definition": "Cumulative sales volume or value of negotiated pharmaceutical products driven by strategic purchasing from medical insurance funds." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2026-02-28", "type": "point" }, "value": 740, "value_text": "7400亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "经济日报记者提问", "quote": "截至今年2月份，医保基金累计为协议期内谈判药品支出5048亿元，带动销售7400亿元，惠及11.7亿人次。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_JDPJRKETGMMTFGGV5QZQKZF26T", "bibtex": "@misc{nhsa2026negotiatedkzf26t,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JDPJRKETGMMTFGGV5QZQKZF26T},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Z2KY4SRVRS4V0XV5GA0GNYZG8F", "url": "https://statorigin.org/stat/stat_Z2KY4SRVRS4V0XV5GA0GNYZG8F", "indicator": { "slug": "new-drug-approvals", "name": "New drug approvals", "definition": "Total number of new medicines granted regulatory marketing authorization for the first time." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 248, "value_text": "248个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "国家药监局药审中心副主任杨志敏则表示，2025年，我国共有248个新药通过临床试验获批上市，涵盖了抗肿瘤、内分泌、精神障碍等18个适应症领域。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_Z2KY4SRVRS4V0XV5GA0GNYZG8F", "bibtex": "@misc{nhsa2025drugnyzg8f,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Z2KY4SRVRS4V0XV5GA0GNYZG8F},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_C77BGGGW97RJ6S1EQC0EH52WY1", "url": "https://statorigin.org/stat/stat_C77BGGGW97RJ6S1EQC0EH52WY1", "indicator": { "slug": "new-drug-clinical-trial-initiation-time-reduction", "name": "New drug clinical trial initiation time reduction", "definition": "Year-over-year reduction in average time required to initiate new drug clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4, "value_text": "4个月", "unit": "months", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "报告显示，2025年我国签署首例受试者知情同意书的新药临床试验1088项，平均启动用时同比缩短4个月。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_C77BGGGW97RJ6S1EQC0EH52WY1", "bibtex": "@misc{nhsa2025drugh52wy1,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_C77BGGGW97RJ6S1EQC0EH52WY1},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_XW2GNFBETTZCC5J6ZFETTMW5WC", "url": "https://statorigin.org/stat/stat_XW2GNFBETTZCC5J6ZFETTMW5WC", "indicator": { "slug": "new-drug-clinical-trials", "name": "New drug clinical trials", "definition": "Total number of clinical trials registered for new drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2997, "value_text": "2997项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_XW2GNFBETTZCC5J6ZFETTMW5WC", "bibtex": "@misc{nhsa2025drugtmw5wc,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XW2GNFBETTZCC5J6ZFETTMW5WC},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_4ZZR5KF92JKQBR8CT8T9YAQDSA", "url": "https://statorigin.org/stat/stat_4ZZR5KF92JKQBR8CT8T9YAQDSA", "indicator": { "slug": "new-drug-clinical-trials", "name": "New drug clinical trials", "definition": "Total number of clinical trials registered for new drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2997, "value_text": "2997项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "我国上半年创新药对外授权约1100亿美元 创历史新高", "quote": "据了解，我国每年新增药物临床试验数量呈持续增长态势，2025年临床试验总量首次突破5000项，创历史新高，其中，新药临床试验2997项，占比57.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_4ZZR5KF92JKQBR8CT8T9YAQDSA", "bibtex": "@misc{nhsa2025drugyaqdsa,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_4ZZR5KF92JKQBR8CT8T9YAQDSA},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_R2CB6FS9JG8J104P1ZEC2JY4ZA", "url": "https://statorigin.org/stat/stat_R2CB6FS9JG8J104P1ZEC2JY4ZA", "indicator": { "slug": "new-drug-clinical-trials-growth-rate", "name": "New drug clinical trials growth rate", "definition": "Year-over-year percentage growth in the number of new drug clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 18, "value_text": "18%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_R2CB6FS9JG8J104P1ZEC2JY4ZA", "bibtex": "@misc{nhsa2025drug2jy4za,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R2CB6FS9JG8J104P1ZEC2JY4ZA},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_F0PZW4WP1KVXCMRVGP9CJS430P", "url": "https://statorigin.org/stat/stat_F0PZW4WP1KVXCMRVGP9CJS430P", "indicator": { "slug": "new-drug-clinical-trials-share", "name": "New drug clinical trials share", "definition": "Share of new drug clinical trials in total registered clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 57.5, "value_text": "57.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_F0PZW4WP1KVXCMRVGP9CJS430P", "bibtex": "@misc{nhsa2025drugjs430p,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_F0PZW4WP1KVXCMRVGP9CJS430P},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_7MT33TNGER7GQT92FRDBECP5TB", "url": "https://statorigin.org/stat/stat_7MT33TNGER7GQT92FRDBECP5TB", "indicator": { "slug": "new-drug-clinical-trials-share", "name": "New drug clinical trials share", "definition": "Share of new drug clinical trials in total registered clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 57.5, "value_text": "57.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "我国上半年创新药对外授权约1100亿美元 创历史新高", "quote": "据了解，我国每年新增药物临床试验数量呈持续增长态势，2025年临床试验总量首次突破5000项，创历史新高，其中，新药临床试验2997项，占比57.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_7MT33TNGER7GQT92FRDBECP5TB", "bibtex": "@misc{nhsa2025drugecp5tb,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7MT33TNGER7GQT92FRDBECP5TB},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_WWD9JN629D19HVNMBPY8Y622MY", "url": "https://statorigin.org/stat/stat_WWD9JN629D19HVNMBPY8Y622MY", "indicator": { "slug": "newly-added-drugs-in-national-reimbursement-drug-list-annual", "name": "Newly added drugs in national reimbursement drug list (annual)", "definition": "Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 114, "value_text": "114", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "经相应程序，本次目录调整新增114种药品，其中50种1类创新药，同时调出了29种临床没有供应或可被其他药物更好替代的药品（其中9种尚有相同治疗主成分的其他剂型在目录内，不减少目录编号）。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_WWD9JN629D19HVNMBPY8Y622MY", "bibtex": "@misc{nhsa2025newlyy622my,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_WWD9JN629D19HVNMBPY8Y622MY},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_9E0WW6E129N2FXQSFJJD8YY9QZ", "url": "https://statorigin.org/stat/stat_9E0WW6E129N2FXQSFJJD8YY9QZ", "indicator": { "slug": "pharmaceutical-industry-r-d-expenditure-growth-rate", "name": "Pharmaceutical industry R&D expenditure growth rate", "definition": "Annual growth rate of research and development expenditures across the pharmaceutical industry." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 23, "value_text": "23%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "经济日报记者提问", "quote": "可以说，这几年不管是从医药行业的利润水平，还是研发投入，都保持了高速增长，医药工业利润总额年均增长11.3%，研发投入年均增长23%，医药创新已经成为新质生产力加快发展的前沿赛道。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_9E0WW6E129N2FXQSFJJD8YY9QZ", "bibtex": "@misc{nhsa2025pharmaceutical8yy9qz,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9E0WW6E129N2FXQSFJJD8YY9QZ},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_SGR69FDFPR5RJHR7PD2WWK1J1P", "url": "https://statorigin.org/stat/stat_SGR69FDFPR5RJHR7PD2WWK1J1P", "indicator": { "slug": "pharmaceutical-industry-total-profit-growth-rate", "name": "Pharmaceutical industry total profit growth rate", "definition": "Annual growth rate of total profits across the pharmaceutical manufacturing industry." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 11.3, "value_text": "11.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "经济日报记者提问", "quote": "可以说，这几年不管是从医药行业的利润水平，还是研发投入，都保持了高速增长，医药工业利润总额年均增长11.3%，研发投入年均增长23%，医药创新已经成为新质生产力加快发展的前沿赛道。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_SGR69FDFPR5RJHR7PD2WWK1J1P", "bibtex": "@misc{nhsa2025pharmaceuticalwk1j1p,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_SGR69FDFPR5RJHR7PD2WWK1J1P},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_X4B46A3ZJBHKPEGZDSJXPKZD80", "url": "https://statorigin.org/stat/stat_X4B46A3ZJBHKPEGZDSJXPKZD80", "indicator": { "slug": "radiopharmaceutical-market-size", "name": "Radiopharmaceutical market size", "definition": "Total market revenue generated by the radiopharmaceutical industry." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2030-01-01", "end": "2030-12-31", "type": "year" }, "value": 26, "value_text": "260亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "forecast", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "11款新靶点新机制创新药涵盖哪些治疗领域", "quote": "杨志还表示，近年来，放射性药物迎来了黄金期。据估计，我国2030年放射性药物行业的市场规模发展将达到260亿元。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2030). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_X4B46A3ZJBHKPEGZDSJXPKZD80", "bibtex": "@misc{nhsa2030radiopharmaceuticalpkzd80,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_X4B46A3ZJBHKPEGZDSJXPKZD80},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HGVQH63ME96G6MHXEXYADER77P", "url": "https://statorigin.org/stat/stat_HGVQH63ME96G6MHXEXYADER77P", "indicator": { "slug": "reimbursement-drug-list-conventional-medicines-annual", "name": "Reimbursement drug list conventional medicines (annual)", "definition": "Total number of conventional chemical medicines included in a reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 1857, "value_text": "1857", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "本次调整后，目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_HGVQH63ME96G6MHXEXYADER77P", "bibtex": "@misc{nhsa2025reimbursementder77p,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HGVQH63ME96G6MHXEXYADER77P},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_GM5F6VDNEF8C5SCDGJVE58G5DR", "url": "https://statorigin.org/stat/stat_GM5F6VDNEF8C5SCDGJVE58G5DR", "indicator": { "slug": "reimbursement-drug-list-total-drugs-annual", "name": "Reimbursement drug list total drugs (annual)", "definition": "Total number of pharmaceutical products covered by a national or public reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 3253, "value_text": "3253", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "本次调整后，目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_GM5F6VDNEF8C5SCDGJVE58G5DR", "bibtex": "@misc{nhsa2025reimbursement58g5dr,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_GM5F6VDNEF8C5SCDGJVE58G5DR},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_F5YSN2AQT30Z0QA9S50QHNBVE7", "url": "https://statorigin.org/stat/stat_F5YSN2AQT30Z0QA9S50QHNBVE7", "indicator": { "slug": "reimbursement-drug-list-traditional-patent-medicines-annual", "name": "Reimbursement drug list traditional patent medicines (annual)", "definition": "Total number of proprietary traditional medicines included in a reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 1396, "value_text": "1396", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "本次调整后，目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_F5YSN2AQT30Z0QA9S50QHNBVE7", "bibtex": "@misc{nhsa2025reimbursementhnbve7,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_F5YSN2AQT30Z0QA9S50QHNBVE7},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_9CT1VV6P3R3GBBMEQWBH1FKR6J", "url": "https://statorigin.org/stat/stat_9CT1VV6P3R3GBBMEQWBH1FKR6J", "indicator": { "slug": "share-of-global-biopharmaceutical-pipeline-snapshot", "name": "Share of global biopharmaceutical pipeline (snapshot)", "definition": "Proportion of global biopharmaceutical research and development pipeline assets originating from a specific country or region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-06-30", "end": "2026-06-30", "type": "point" }, "value": 30, "value_text": "30%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "我国上半年创新药对外授权约1100亿美元 创历史新高", "quote": "国家药监局药品注册司副司长蓝恭涛介绍，我国在研新药数量约占全球30%，位列全球第二；中国医药产业创新效率居世界前列。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_9CT1VV6P3R3GBBMEQWBH1FKR6J", "bibtex": "@misc{nhsa2026share1fkr6j,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9CT1VV6P3R3GBBMEQWBH1FKR6J},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_MZRV2VB8GAQYF7Z8WHVHC588BE", "url": "https://statorigin.org/stat/stat_MZRV2VB8GAQYF7Z8WHVHC588BE", "indicator": { "slug": "top-50-global-pharmaceutical-companies-count", "name": "Top 50 global pharmaceutical companies count", "definition": "Number of pharmaceutical enterprises ranked among the world's top 50 pharmaceutical companies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-04-15", "end": "2026-04-15", "type": "point" }, "value": 6, "value_text": "6席", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "红星新闻记者提问", "quote": "随着产业链关键核心技术攻关的加快推进，行业龙头企业加速崛起，现在全球前50医药企业我们国家占有6席。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_MZRV2VB8GAQYF7Z8WHVHC588BE", "bibtex": "@misc{nhsa2026pharmaceuticalc588be,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_MZRV2VB8GAQYF7Z8WHVHC588BE},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 73, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=national-healthcare-security-administration with a cursor to page through everything." } }